MarketVIEW: Epstein-barr virus vaccines (CAT: VAMV056)

Product Name : MarketVIEW: Epstein-barr virus vaccines
Description : Global vaccine commercial opportunity assessment
Contents : Executive presentation (.pdf) + 1 forecast model (.xls)
Therapeutic Area : Novel vaccines
Publication date : July 2015
Catalogue No : VAMV056

Background

Epstein-barr virus (EBV) is a herpesvirus family that exclusively infects humans, over 95% of adults worldwide are infected. Primary EBV infections that occur in adolescence or early adulthood often result in infectious mononucleosis (IM), characterized by pharyngitis, cervical lymph node enlargement, fatigue and fever; complications can occur in around 1% of patients. Infectious mononucleosis is associated with an increased risk of Hodgkin lymphoma. EBV is also associated with a variety of malignancies, including gastric carcinoma, nasopharyngeal carcinoma, Hodgkin lymphoma and Burkitt lymphoma. EBV caused ~1% of all global cancers in 2002. EBV also causes Post transplant lymphoproliferative disorder (PTLD), a complication of solid organ transplants (SOT) and allogeneic hematologic stem cell transplants (HSCT).

This MarketVIEW product contains a comprehensive MS Excel-based model + summary presentation that forecasts the potential commercial value of Epstein-barr virus (EBV) vaccines across Western economies until 2035. The model contains value ($ m) and volume (mio doses) predictions per vaccine target segment along with timeframe, pricing and penetration estimates for three target product profiles (TPPs). The product also includes an in depth review of latest EBV epidemiological trends, treatments/guidelines and latest developments in R&D.
Methodology

VacZine Analytics has closely monitored all significant source material pertaining to Ebola virus, current and past outbreaks. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by VacZine Analytics in the field of novel vaccines has also been utilised.

PRODUCT CONTENTS:
Published July 2015 (CAT No: VAMV056)

****This product is composed of one forecast model (.xls) and a summary presentation (.pdf)

Contents
Author’s note
Executive Summary
Commercial model: key model outputs
EBV vaccines: global sales, by target population, 2015-2035 ($m)
EBV vaccines: global sales, seronegative adolescents, 2015-2035 ($m)
EBV vaccines: global sales, college students, 2015-2035 ($m)
EBV vaccines: global sales, transplant recipients, 2015-2035 ($m)
EBV vaccines: global sales, cancers, 2015-2035 ($m)
EBV vaccines: global volume per segment, 2015-2035 (doses)
EBV vaccines: modeling commercial potential
Markets for EBV vaccines
The role of an EBV vaccine
EBV vaccines: potential access points
EBV prophylactic vaccine: target product profile
EBV cancer therapeutic vaccine: target product profile
EBV transplant therapeutic vaccine: target product profile
EBV vaccines: unresolved questions
Key model parameters
Dosing, pricing, penetration and compliance rates
Vaccine R&D pipeline
Vaccine R&D pipeline: clinical studies
EBV: disease background and epidemiology
EBV: the pathogen
EBV antibody prevalence, by race/ethnicity and age, 2003-10, US
Epstein-barr virus: immune response
Epstein-barr virus: associated with malignancies
Global number of infection-attributable cancer cases, 2002
Epstein-barr virus associated cancers: statistics
Global deaths due to EBV-attributable malignancies, by cancer type, region and age, 2010
Epstein-barr virus: EBV malignancies by region
Continued.........

Epstein-barr virus malignancies: deaths by age
Post transplant lymphoproliferative disorder (PTLD)
Epstein-barr virus: PTLD incidence in kidney transplants
Infectious mononucleosis
Epstein-barr virus: IM associations
Methodology/backup slides
Bibliography
About VacZine Analytics
Disclaimer

PAGES: ~54 slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model TX vaccine (MS Excel-based)

Title sheet
Charts – value
Charts – by country (2025)
Value summary
Charts – volume
Volume summary
Adolescents =>
US (11 years)
Germany
France
UK
Italy
Spain
Other Europe
College students =>
US
Germany
France
UK
Italy
Spain
Other Europe
Transplants =>
US
Germany
France
UK
Italy
Spain
Other Europe
Cancers =>
US
Germany
France
UK
Continued..........  

Italy  
Spain  
Other Europe  
Sources  
Total population  
11-year-olds  
Cancer incidence  
Number of US transplants  
Forecast HSCTs  
Forecast kidney transplants  
Country income groups  
PTLD - incidence paediatrics  
Global cancers  
Global EBV deaths  
Back page  

Worksheets ~ 55 interconnected
PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD $8995.00/ GBP £5800.00* (Region license)*
- PRESENTATION OR MODEL ONLY - USD $4995 (Region license)*

*Indicative rate only. Prevailing rate applied to date of transaction.
*A region is North America, Europe or ROW
For orders in the UK, VAT at 20.0% will be added to final invoice total

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the TERMS and CONDITIONS of purchase.

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and the “spiral logo” are UK Registered Trademarks, 2009


11. IARC. Epstein-Barr virus. Available at: monographs.iarc.fr/ENG/Monographs/vol100B/mono100B-6.pdf


TERMS and CONDITIONS:
VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.
3. Cancellation policy. The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. Cancellation rights: For finished documents - a Clients cancellation rights will last for seven working days counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.
5. Invoicing will 100% after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within thirty days of the invoice date.
7. All proposals are quoted in $USD dollars or £GBP and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master TERMS and CONDITIONS available upon request.

VacZine Analytics
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com
About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009